CoChat

Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

Open access
Bogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N. K., Mahapatra, A. K., Suri, A., Balasubramaniam, A., Nair, S., Oliushine, V., Parfenov, V., Poverennova, I., Zaaroor, M., Jachimczak, P., Ludwig, S., Schmaus, S., Heinrichs, H., Schlingensiepen, K.- H., the Trabedersen Glioma Study Group · 2011 · Neuro-Oncology

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

This randomized, open-label, active-controlled, dose-finding phase IIb study evaluated the efficacy and safety of trabedersen (AP 12009) administered intratumorally by convection-enhanced delivery compared with standard chemotherapy in patients with recurrent/refractory high-grade glioma. One hundred and forty-five patients with central reference histopathology of recurrent/refractory glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA) were randomly assigned to receive trabedersen at doses of 10 or 80 µM or standard chemotherapy (temozolomide or procarbazine/lomustine/vincristine). Primary endpoint was 6-month tumor control rate, and secondary endpoints included response at further timepoints, survival, and safety. Six-month tumor control rates were not significantly different in the entire study population (AA and GBM). Prespecified AA subgroup analysis showed a significant benefit regarding the 14-month tumor control rate for 10 µM trabedersen vs chemotherapy (p= .0032). The 2-year survival rate had a trend for superiority for 10 µM trabedersen vs chemotherapy (p = .10). Median survival for 10 µM trabedersen was 39.1 months compared with 35.2 months for 80 µM trabedersen and 21.7 months for chemotherapy (not significant). In GBM patients, response and survival results were comparable among the 3 arms. Exploratory analysis on GBM patients aged ≤55 years with Karnofsky performance status >80% at baseline indicated a 3-fold survival at 2 and 3 years for 10 µM trabedersen vs chemotherapy. The frequency of patients with related or possibly drug-related adverse events was higher with standard chemotherapy (64%) than with 80 µM trabedersen (43%) and 10 µM trabedersen (27%). Superior efficacy and safety for 10 µM trabedersen over 80 µM trabedersen and chemotherapy and positive risk-benefit assessment suggest it as the optimal dose for further clinical development in high-grade glioma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/noq142

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Efficacy results in patients with AA (primary efficacy population, n= 39). (A) Tumor control rates (complete response + partial response + stable disease) at months 6 and 14. *Comparison between 10 µM trabedersen and standard chemotherapy: p= .0032. (B) Kaplan–Meier plot for patients treated with 10 µM trabedersen (n= 12) vs 80 µM trabedersen (n= 15). (C) Kaplan–Meier plot for patients treated with 10 µM trabedersen (n= 12) vs standard chemotherapy (n= 12). (D) Overall survival rates.
Fig. 1. Efficacy results in patients with AA (primary efficacy population, n= 39). (A) Tumor control rates (complete response + partial response + stable disease) at months 6 and 14. *Comparison between 10 µM trabedersen and standard chemotherapy: p= .0032. (B) Kaplan–Meier plot for patients treated with 10 µM trabedersen (n= 12) vs 80 µM trabedersen (n= 15). (C) Kaplan–Meier plot for patients treated with 10 µM trabedersen (n= 12) vs standard chemotherapy (n= 12). (D) Overall survival rates.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Fontana A Bodmer S Frei K Malipiero U Siepl C Expression of TGF-beta 2 in human glioblastoma: a role in resistance to immune rejection? Ciba Found Symp. 1991 157 232 241 1649035

Cited by

See all 442

Metadata

Authors
Bogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N. K., Mahapatra, A. K., Suri, A., Balasubramaniam, A., Nair, S., Oliushine, V., Parfenov, V., Poverennova, I., Zaaroor, M., Jachimczak, P., Ludwig, S., Schmaus, S., Heinrichs, H., Schlingensiepen, K. H., & the Trabedersen Glioma Study Group
Affiliations
  • University of Regensburg (DE)
  • Sanjay Gandhi Post Graduate Institute of Medical Sciences (IN)
Corresponding author
Bogdahn, U.
Venue
Neuro-Oncology
Published
2010-10-27
Volume
13
Issue
1
Pages
132-142
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W2116583846
Cited by
433
References
34
Citations by year
2026: 13 · 2025: 20 · 2024: 28 · 2023: 29 · 2022: 28 · 2021: 21 · 2020: 33 · 2019: 24 · 2018: 24 · 2017: 31 · 2016: 22 · 2015: 39 · 2014: 34 · 2013: 31 · 2012: 33
FWCI
12.38
Type
journal article
Language
en
Open access
Locations
  • Neuro-Oncology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
Keywords
high-grade glioma, anaplastic astrocytoma, temozolomide, procarbazine, lomustine, and vincristine, tumor control rate, survival, dose-finding, adverse events
MeSH terms
Adult, Antineoplastic Agents, Brain Neoplasms, Female, Glioblastoma, Humans, International Agencies, Male, Middle Aged, Neoplasm Recurrence, Local, Oligodeoxyribonucleotides, Thionucleotides, Survival Rate, Treatment Outcome, Transforming Growth Factor beta2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.